產(chǎn)品訂購信息：
英文名稱  Anti-phospho-SCNN1B(Ser633) 

中文名稱   磷酸化上皮鈉通道β2抗體品牌 

別    名  SCNN1B(phospho S633); Amiloride sensitive sodium channel subunit beta; Beta NaCH; ENaC beta; ENaCB; Epithelial Na(+) channel subunit beta; Epithelial Na+ channel beta subunit; Epithelial Na+ channel subunit beta; Epithelial sodium channel beta 2 subunit; Epithelial sodium channel beta 3 subunit; Nonvoltage gated sodium channel 1 beta subunit; Nonvoltage gated sodium channel 1 subunit beta; SCNEB; SCNN 1B; SCNNB_HUMAN; Sodium channel nonvoltage gated 1 beta (Liddle syndrome); Sodium channel nonvoltage gated 1 beta; SCNNB_HUMAN.

濃    度   1mg/1ml

規(guī) 格  0.1ml/100μg

抗體來源   Rabbit

克隆類型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Dog, Pig, Cow, Guinea Pig, G 

產(chǎn)品類型   一抗 磷酸化抗體  

研究領(lǐng)域     免疫學(xué) 神經(jīng)生物學(xué) 細(xì)胞膜受體

蛋白分子量  predicted molecular weight: 73kDa

性    狀   Lyophilized or Liquid

免 疫 原 KLH conjugated Synthesised phosphopeptide derived from human SCNN1B around the phosphorylation site of Ser633 

亞    型   IgG

純化方法   affinity purified by Protein A

儲 存 液   0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

磷酸化上皮鈉通道β2抗體品牌 產(chǎn)品應(yīng)用    WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 SCNN1B is a subunit of the epithelial sodium channel, ENaC. ENac has high sodium selectivity, low conductance, and amiloride sensitivity. The functional channel of ENaC is composed of at least 3 subunits, alpha (SCNN1A), beta (SCNN1B), and gamma (SCNN1G). The 3 subunits show sequence similarities to one another, indicating descent from a common ancestral gene. Each encodes a protein containing 2 transmembrane domains, with intracellular amino and carboxyl termini.

Function : Sodium permeable non-voltage-sensitive ion channel inhibited by the diuretic amiloride. Mediates the electrodiffusion of the luminal sodium (and water, which follows osmotically) through the apical membrane of epithelial cells. Controls the reabsorption of sodium in kidney, colon, lung and sweat glands. Also plays a role in taste perception.

Subunit : Probable heterotrimer containing one alpha, one beta and one gamma subunit. A delta subunit can replace the alpha subunit. Interacts with the WW domains of NEDD4, NEDD4L, WWP1 and WWP2. Interacts with the full length immature form of PCSK9 (pro-PCSK9).

Subcellular Location : Apical cell membrane; Multi-pass membrane protein. Note=Apical membrane of epithelial cells.

Post-translational modifications : Phosphorylated on serine and threonine residues (By similarity).

DISEASE : Pseudohypoaldosteronism 1, autosomal recessive (PHA1B) [MIM:264350]: A rare salt wasting disease resulting from target organ unresponsiveness to mineralocorticoids. PHA1B is a severe form involving multiple organ systems, and characterized by an often fulminant presentation in the neonatal period with dehydration, hyponatremia, hyperkalemia, metabolic acidosis, failure to thrive and weight loss. Note=The disease is caused by mutations affecting the gene represented in this entry. The degree of channel function impairment differentially affects the renin-aldosterone system and urinary Na/K ratios, resulting in distinct genotype-phenotype relationships in PHA1 patients. Loss-of-function mutations are associated with a severe clinical course and age-dependent hyperactivation of the renin-aldosterone system. This feature is not observed in patients with missense mutations that reduce but do not eliminate channel function. Markedly reduced channel activity results in impaired linear growth and delayed puberty (PubMed:18634878).

Liddle syndrome (LIDDS) [MIM:177200]: Autosomal dominant disorder characterized by pseudoaldosteronism and hypertension associated with hypokalemic alkalosis. The disease is caused by constitutive activation of the renal epithelial sodium channel. Note=The disease is caused by mutations affecting the gene represented in this entry.

Bronchiectasis with or without elevated sweat chloride 1 (BESC1) [MIM:211400]: A debilitating respiratory disease characterized by chronic, abnormal dilatation of the bronchi and other cystic fibrosis-like symptoms in the absence of known causes of bronchiectasis (cystic fibrosis, autoimmune diseases, ciliary dyskinesia, common variable immunodeficiency, foreign body obstruction). Clinical features include sub-normal lung function, sinopulmonary infections, chronic productive cough, excessive sputum production, and elevated sweat chloride in some cases. Note=The disease is caused by mutations affecting the gene represented in this entry.

Similarity : Belongs to the amiloride-sensitive sodium channel (TC 1.A.6) family. SCNN1B subfamily.

Database links :

UniProtKB/Swiss-Prot: P51168.2

Entrez Gene: 6338 Human

Omim: 600760 Human

SwissProt: P51168 Human

Unigene: 414614 Human

Anti-TRAF2/TNF-R2 /FITC 熒光素標(biāo)記壞死因子受體相關(guān)因子2抗體IgGMulti-class antibodies規(guī)格： 0.2ml

BRCA2(Breast cancer susceptbility gene 2) 癌易感基因2抗原Multi-class antibodies規(guī)格： 0.5mg

壞死因子相關(guān)凋亡誘導(dǎo)配體/凋亡素2配體抗體 Anti-TRAIL/Apo2L 0.1ml

SPRR1a 英文名稱： 角質(zhì)蛋白α抗體 0.1ml

EBF2 英文名稱： 早期B淋巴細(xì)胞因子2抗體 0.2ml

Rhesus antibody Rh phospho-IRS1(Tyr1222) 磷酸化受體底物-1抗體 規(guī)格 0.1ml

BRCA2(Breast cancer susceptbility gene 2) 癌易感基因2抗原Multi-class antibodies規(guī)格： 0.5mg

Anti-Phospho-Rb (Ser807/Ser811)/FITC 熒光素標(biāo)記磷酸化視網(wǎng)膜母細(xì)胞瘤相關(guān)蛋白1抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rabbit Anti-Guinea IgM Whole serum 兔抗豚鼠IgM抗血清Multi-class antibodies規(guī)格： 1ml

KB抑制蛋白α抗體 Anti-IKB α 0.2ml

Goat anti-Bovine IgG whole serum 羊抗IgG抗血清 1ml

FAM134B 英文名稱： FAM134B蛋白抗體 0.2ml

Rhesus antibody Rh phospho-PTPRA(Ser180) 磷酸化酪氨酸磷酸酶α抗體 規(guī)格 0.1ml

Rabbit Anti-Guinea IgM Whole serum 兔抗豚鼠IgM抗血清Multi-class antibodies規(guī)格： 1ml

IRF-1(Interferon regulatory factor-1) 干擾素調(diào)節(jié)因子抗原Multi-class antibodies規(guī)格： 0.5mg

Anti-ADNP/NAP 活性依賴的神經(jīng)保護(hù)肽抗體Multi-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh Phospho-cdc2 (Ser39) 磷酸化周期素依賴激酶2抗體 規(guī)格 0.1ml

品名 規(guī)格 備注

VE Cadherin 英文名稱： 上皮型鈣粘附分子抗體 0.1ml

DREF 英文名稱： DNA復(fù)制相關(guān)元件結(jié)合因子抗體 0.2ml

Anti-ADNP/NAP 活性依賴的神經(jīng)保護(hù)肽抗體Multi-class antibodies規(guī)格： 0.2ml

IFNB1 Protein Mouse 重組小鼠 IFNB1 / IFN-beta / Ierferon beta 蛋白 (Fc 標(biāo)簽)

大鼠腦內(nèi)皮細(xì)胞完全培養(yǎng)基 100mL

FCGRT & B2M Others Mouse 小鼠 FCGRT & B2M Heterodimer 人細(xì)胞裂解液 (陽性對照)

LLC-PK1豬腎近曲小管上皮細(xì)胞 LLC-PK1 porcine kidney proximal tubular epithelial cells M199+3% FBS/DMEM+F12+12%FBS

C6, 大鼠腦細(xì)胞

MDA-MB-468-06(人癌細(xì)胞) 5×106cells/瓶×2 Y1(腎上腺皮質(zhì)細(xì)胞)

CM-R103大鼠腦平滑肌細(xì)胞完全培養(yǎng)基100mL

CHST11 Others Human 人 CHST11 / C4ST-1 桿狀病毒-昆蟲細(xì)胞裂解液 (陽性對照)

小鼠小膠質(zhì)細(xì)胞MM

SV40轉(zhuǎn)化的非洲綠猴腎細(xì)胞;COS-1 膀胱變移細(xì)胞癌，T-24細(xì)胞 U251(細(xì)胞)

EB病毒轉(zhuǎn)化的人B淋巴細(xì)胞;KMY0927

EFNB2 Others Mouse 小鼠 EFNB2 / EphrinB2 人細(xì)胞裂解液 (陽性對照)

磷酸化上皮鈉通道β2抗體品牌 IFNB1 Protein Mouse 重組小鼠 IFNB1 / IFN-beta / Ierferon beta 蛋白 (Fc 標(biāo)簽)

大鼠腦內(nèi)皮細(xì)胞完全培養(yǎng)基 100mL

FCGRT & B2M Others Mouse 小鼠 FCGRT & B2M Heterodimer 人細(xì)胞裂解液 (陽性對照)

LLC-PK1豬腎近曲小管上皮細(xì)胞 LLC-PK1 porcine kidney proximal tubular epithelial cells M199+3% FBS/DMEM+F12+12%FBS

C6, 大鼠腦細(xì)胞

MDA-MB-468-06(人癌細(xì)胞) 5×106cells/瓶×2 Y1(腎上腺皮質(zhì)細(xì)胞)

抗體的生物素化標(biāo)記實驗要點：

1. 磷酸化上皮鈉通道β2抗體品牌 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；

2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個不同的分子比來篩選最適條件；

3.用NHSB量過量也是不利的,抗原的結(jié)合位點可能因此被封閉,導(dǎo)致抗體失活；

4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等；

5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點時,或位于酶的催化位點時,生物素化會降低或損傷抗體蛋白的結(jié)合力或活性；

6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價結(jié)合；

7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；

8.在細(xì)胞的熒光標(biāo)記實驗中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細(xì)胞可導(dǎo)致高本底。

抗體的鑒定：

1）磷酸化上皮鈉通道β2抗體品牌 抗體的效價鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗,酶聯(lián)免疫吸附試驗等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴(kuò)散試驗來鑒定。

2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識別能力?？贵w的特異性高,它的識別能力就強。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計算各自的結(jié)合率,求出各自在IC50時的濃度,并按公式計算交叉反應(yīng)率。 

如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。

3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測定對抗體的篩選,確定抗體的用途,驗證抗體的均一性等均有重要意義。